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John Dick and colleagues demonstrated in the mid-
1990s that only a small fraction of human acute 
myeloid leukemia tumour cells were capable of 
initiating and sustaining tumour growth following 
transplantation into an immunocompromised murine 
host (Lapidot et al., 1994; Bonnet and Dick, 1997). 
While the remaining tumour cells were able to 
proliferate, their proliferative potential was limited and 
they were incapable of sustaining tumour growth. In 
addition to their capability to proliferate, these 
leukemia-initiating cells possessed the ability to self-
renew and were able to give rise to multiple 
heterogeneous progeny. Interestingly, these cells were 
identifiable by surface marker reminiscent of SCID-
repopulating cells rather than committed precursors. 
Given their functional and morphologic similarity to
normal hematopoietic stem cells, Bonnet and Dick 
called these cells leukemic cancer stem cells. Further, 
they hypothesized that the cellular heterogeneity found 
within this cancer reflected a hierarchy that 
recapitulates normal hematopoietic development and 
that cell identity within a cancer –as defined by a stem-
like or a more committed state– had functional 
relevance for a cell's ability to drive tumour growth. 
Since then, numerous hematologic and solid tumours –
including acute lymphoblastic leukemia (Cobaleda et 
al., 2000; Cox et al., 2004; Castor et al., 2005), breast 
(Al-Hajj et al., 2003), colon (O'Brien et al., 2007; 
Ricci-Vitiani et al., 2007) and lung cancer (Eramo et 
al., 2008), melanoma (Fang et al., 2005), and primary 
brain tumours (Singh et al., 2004)– have been found to 
harbor cancer stem cells. The cancer stem cell 
hypothesis has been forwarded as an alternative to the 
clonal evolution model of cancer development. In 
primary brain tumours, the cancer stem cell hypothesis 
has important ramifications for how we think about 
disease treatment and how we understand disease  
recurrence and progression. Here, I will review the
current literature regarding cancer stem cells in primary 
brain tumours and discuss the relevance of the cancer 
stem cell hypothesis and clonal evolution model to their 
biology. Then, I will review the question of cell-of
origin in primary brain tumours. Finally, I will bring up 
questions regarding the implications of the cancer st m 
cell hypothesis for glioma biology that must be 
addressed with future studies. 
Brain tumour stem cells: the 
evidence 
The presence of cancer stem cells in adult glioma was
established by concomitant independent work in the 
labs of Drs. Peter Dirks and Angelo Vescovi. Both 
groups applied techniques from the neural stem cell 
biology field to isolate brain tumour stem cells 
(BTSCs) from human surgical specimens, namely, by 
enrichment of BTSCs from dissociated tumour cells as 
gliomaspheres grown on non-adherent plates in serum-
free media supplemented with the growth factors EGF 
and FGF (Galli et al., 2004; Singh et al., 2004). These 
cells, when exposed to growth factor withdrawal or 
serum, lost their stem-like features and gave rise to 
more differentiated progeny resembling normal 
committed neuroepithelial cells. In addition, when 
transplanted into the brains of immunocompromised 
mice, these cells gave rise to brain tumours that 
pathologically resembled the parent tumour and that
could be propogated by serial dissociation and 
transplantation. Further, the Dirks lab found that the
cell surface protein, CD133, could be used as a marker 
for the tumorigenic subpopulation in human tumours. 
Since that time, the Dirks group has shown that these 
cells can also be isolated and propagated as an adherent 
monolayer (Pollard et al., 2009). 
That the BTSC population can be enriched by growth 
in serum-free, growth factor-supplemented media 
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speaks to the hierarchical similarities between tumo r 
cells in high-grade gliomas and stem and committed 
neuroepithelial cells in the normal brain. This technique 
is also used for enrichment of neural stem cells from 
the mouse subventricular zone (Reynolds and Weiss, 
1992) and subgranular zone (Bonaguidi et al., 2008). In 
addition, normal neural stem cells differentiate into 
neurons, astrocytes and oligodendrocytes following 
withdrawal of growth factors or exposure to serum. 
Surprisingly, BTSCs appear capable of 
"differentiating" as well. BTSCs grown in these 
conditions stop expressing cellular markers of stem-
ness, and instead take on the immunohistochemical and 
sometimes morphological properties of committed 
cells. What these cancer-derived "neurons", 
"astrocytes", and "oligodendrocytes" represent remains 
unclear. Some data suggest that these cells have exited 
the cell cycle and are in fact post-mitotic. Using murine 
xenotransplantation as the measure of tumourigenicity, 
these populations appear to be non-tumorigenic. 
Certainly, prolonged exposure to serum appears to give 
rise to or select for a cell population different from the 
original tumour, and these populations, when they do 
give rise to tumours following xenotransplantation, 
result in lesions that resemble the more mesenchymal 
tumours seen with implantation of many traditional 
glioma cell lines rather than a true glioblastoma (Lee et 
al., 2006). These findings would suggest that BTSCs, 
as reflected by the cells enriched by growth-factor 
supplemented, serum-free media culture, are the 
primary drivers of glioblastoma growth in vivo. 
Interestingly, many of the properties of BTSCs within 
the tumour microenvironment recapitulate what we 
know about neural stem cells. Like neural stem cells, 
BTSCs have been shown to be resistant to radiation- 
and chemotherapy-induced DNA damage (Bao et al., 
2006a; Eramo et al., 2006; Liu et al., 2006). In vivo, 
BTSCs appear to reside within a vascular niche (Bao et 
al., 2006b; Calabrese et al., 2007) reminiscent of he 
normal neural stem cell niche (Shen et al., 2008; 
Tavazoie et al., 2008), and appear to respond to 
changes in the extracellular matrix (Lathia et al., 2010) 
–for example, to integrins– that are relevant to normal 
neural stem cell biology (Kazanis et al., 2010). Finally, 
many of the molecular pathways that are central to 
gliomagenesis –such as p53, Ras, PTEN, and Rb– are 
also relevant to normal development and maintenance 
of adult neural stem cell homeostasis (Meletis et al., 
2006; Molofsky et al., 2006; Quinones-Hinojosa et al., 
2006; Gil-Perotin et al., 2009; Gregorian et al., 2009). 
The cell-intrinsic and micro-environmental similarities 
between BTSCs suggests that the study of neural stem
cell biology might have resonance for our 
understanding of primary brain tumours, and these 
factors must be taken into account in our attempt to 
develop better and more effective therapies against 
them. 
BTSCs and tumour recurrence 
Expression of the polycomb group protein Bmi1 by 
neural stem cells has been found to enhance ATM 
recruitment to the chromatin in these cells and increase 
the rate of gamma H2AX foci resolution, resulting in 
resistance to radiation-induced DNA damage and cell 
death (Facchino et al., 2010). Neural stem cells also 
express high levels of ATP-dependent drug efflux 
pumps belonging to the superfamily of ATP-binding 
cassette (ABC) transporters such as ABCB1 (also 
known as MDR1) and ABCG2 (Islam et al., 2005a; 
Islam et al., 2005b). These transporters act as an 
effective salve against chemotherapeutic agents, which 
undergo rapid efflux from neural stem cells. 
BTSCs have similarly been found to be preferentially 
resistant to radiation- or chemotherapy-induced cell
death compared to non-stem glioma cells (Bao et al., 
2006a; Eramo et al., 2006; Liu et al., 2006). Treatment 
of mice harboring a virally induced primary tumour 
with chemotherapy and radiation results in expansion 
of the side population following therapy (Bleau et al., 
2009). Conventional treatment of high-grade gliomas in 
humans similarly appears to result in expansion of the 
BTSC population, as measured by CD133-positivity, 
suggesting that these cells preferentially survive 
chemotherapy and radiation (Tamura et al., 2009; 
Pallini et al., 2011). Interestingly, analysis of 
glioblastomas within the TCGA database revealed an 
evolution of tumours toward a more mesenchymal 
phenotype on recurrence. In breast cancer, the 
epithelial-mesenchymal transition has been found to 
drive cells toward a more stem-like identity (Mani et 
al., 2008). It is intriguing to speculate that the 
mesenchymal transition in glioblastomas following 
chemoradiation also reflects an enrichment of stem-like 
cells in these tumours. 
In examining the radioresistance of BTSCs, the Rich 
group found that CD133+ cells repaired DNA damage 
faster than CD133- cells (Bao et al., 2006a). The 
difference between these two groups was ameliorated 
by treatment with DBH, an inhibitor of CHK1/CHK2. 
Of note, they found that not all CD133+ cells were 
radioresistant, suggesting that this population is itself 
heterogeneous. Their results indicate that BTSC 
resistance to radiation-induced cell death is due at l ast 
in part to an elevated and more rapid DNA damage 
repair response, and that the epigenetic  
landscape necessary for this response to occur is 
intrinsic to BTSC identity. 
The mechanisms underlying BTSC chemoresistance 
are less defined. Eramo et al. found human BTSCs to 
be resistant to cell death following treatment with 
multiple different chemotherapeutic agents in vitro 
(Eramo et al., 2006). In their model, chemoresistance 
appeared to be attributable to abnormalities in cell
death pathways rather than to impaired drug uptake or 
enhanced drug efflux. Indeed, Liu et al. found  
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increased levels of expression of the DNA repair genes, 
MGMT and BCRP1, in CD133+ glioma cells (Liu et 
al., 2006). How to reconcile these findings with oter 
data showing increased expression of drug efflux 
pumps in BTSCs (Bleau et al., 2009) is unclear. 
Regardless, these findings have tremendous import to 
our understanding of glioma recurrence and to our 
efforts to establish more effective treatment regimens 
for patients with this disease. 
Differentiation therapy for GBM 
Dirks has proposed that multi-potentiality is a defining 
element of stem-ness in glioma cells (Dirks, 2010). In 
vitro, BTSCs have been shown to be capable of givin 
rise cells resembling neurons, astrocytes, and 
oligodendrocytes, perhaps explaining the cellular 
heterogeneity once encounters in these tumours in vivo.
If stem-ness confers treatment resistance to a 
subpopulation of glioma cells that seems responsible 
for disease recurrence and progression, then therapies 
directed against stem-cell identity may improve the
efficacy of our current treatments. Effective cancer 
therapy may depend upon treating biologically distinct 
compartments within a glioblastoma that are sensitive 
to different types of therapies. It is unlikely tha 
targeting of the BTSC subpopulation alone will lead to 
cancer remission. In other words, the goal for brain 
tumour treatment may need to be elimination or 
compromise of all tumour cells. 
The clinical value of differentiation therapy has been 
best demonstrated by the use of retinoic acid in the 
treatment of acute promyelocytic leukemia (APL). APL 
is associated with a stereotypic chromosomal 
translocation event in which the PML gene is fused to 
the retinoic acid receptor α (RARα), resulting in the 
production of a PML-RARα chimeric protein. PML 
and RARα are both known to have fundamental roles in 
myeloid differentiation, and to have tumour-suppressor 
and cell-growth-suppressive activities. The PML-
RARα fusion protein acts as a double dominant 
negative oncogenic product, as is able to interfere with 
both the PML and RAR/RXR-RA pathways (Abbot et 
al., 1994; Dyck et al., 1994). Treatment of APL cells 
with RA results in inactivation of the PMLÂ-RARα 
fusion protein, myeloid differentiation of APL cells, 
and increased success  
rates with consolidation chemotherapy, presumably 
because of increased chemosensitivity of these 
"differentiated" cells. 
Many pathways relevant to cell identity in neural stem 
cells –such as transforming growth-factor beta (TGF-
β), leukemia inhibiting factor (LIF), sonic hedgehog 
(Shh), Notch and bone morphogenetic factor (BMP)– 
appear to have complementary roles in BTSC biology. 
Increased activation of the TGF-β, LIF and Shh 
pathways has been found to be associated with worse 
prognosis and increased stem-ness in patients with 
glioblastoma (Bruna et al., 2007; Xu et al., 2008; 
Penuelas et al., 2009; Anido et al., 2010; Carro et al., 
2010). Inhibition of the Notch pathway by treatment of 
BTSCs with a γ-secretase inhibitor rendered these cells 
more sensitive to radiation (Wang et al., 2010) and 
temozolomide chemotherapy (Ulasov et al., 2011), 
suggesting that Notch signaling is necessary for 
maintenance of stem-ness in these cells. Similarly, the 
Vescovi group found that activation of the BMP 
pathway in BTSCs resulted in astrocytic differentiation 
and loss of tumorigenicity (Piccirillo et al., 2006). 
Whether these findings can be translated into patient 
care remains to be determined. In fact, inactivating 
mutations in these traditional developmental pathways 
may prove to be driver events in gliomagenesis, and a 
block in differentiation may be resistant to pathway 
activation, as is the case in APL in which the PML 
gene is lost (Wang et al., 1998; Collins, 2008) andin 
gliomas harboring methylation of the BMPR1b 
receptor (Lee et al., 2008). Regardless, adjuvant 
differentiation therapy could very well have a role in 
our future treatments of glioblastoma, and could 
improve the efficacy of our current therapies. 
Glioma recurrence and progression 
Recent work from the Morrison lab demonstrated that
xenotransplantation might not be an appropriate proxy 
for tumourigenicity (Quintana et al., 2008). Using 
freshly dissociated human melanoma cells, Quintana et 
al. found much higher engraftment and tumour 
formation rates following transplantation into 
NOD/SICD Il2rg-/-rather than NOD/SCID mice. 
Tumour engraftment could be further enhanced by co-
injection with Matrigel. Many of the cells that gave rise 
to tumours following transplantation in Matrigel did 
not possess the phenotypic characteristics of melanom  
stem cells, and in fact, many of them instead resembl d 
committed melanocytes, leading the authors to 
conclude that they were unable to identify any 
phenotypic differences to distinguish tumourigenic 
from non-tumourigenic melanoma cells. They 
postulated that the limited or absent tumourigenic 
potential ascribed to non-stem cancer cells is in fact an 
artifact of the assay system employed to measure 
tumourigenicity. 
What relevance do these findings have for our 
understanding of the cancer stem cell hypothesis in 
glioblastoma? First, these data do show that 
tumourigenic potential is graded and varies between 
phenotypically heterogeneous cells –some melanoma 
cells were capable of driving tumour growth following 
naked transplantation in an NOD/SCID host, while 
others could form tumours only following 
transplantation in Matrigel into an NOD/SICD Il2rg-/-
mouse. What sort of environmental challenges face a 
glioblastoma cell attempting to proliferate within the 
brain of its autologous host? Xenotransplantation into 
an NOD/SCID host may be unmasking cell populations 
capable, for example, of invasion into the normal br in, 
rather than cells able to drive growth within the tumour 
mass. It seems overly optimistic to believe that only a 
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small population of tumour cells in a glioblastoma is 
capable of driving tumour growth within this relatively 
familiar environment. I would propose instead that the
cellular hierarchy in glioblastoma is associated with a 
graded difference in tumourigenicity, and that the stem-
cell identity that defines BTSCs is one –and certainly 
not the only– mechanism of treatment resistance in this 
disease. 
While CD133+ cells appear to be enriched at 
glioblastoma recurrence, even recurrent tumours are 
heterogeneous in nature. Does this hetereogeneity 
reflect a repopulation of the tumour by treatment-
resistant BTSCs? Or are the remaining cells reflectiv  
of numerous clones –among them, a BTSC 
subpopulation– that have survived treatment? If the 
latter, then stem-ness is only one of many mechanisms 
by which tumour cells evade radiation- and 
chemotherapyÂ-induced cell death, and studies 
examining genetic drift in tumour cells remain 
necessary and very relevant to cancer biology. 
BTSCs and the cell-of-origin 
Numerous historical observers have speculated that 
glioblastoma is a disease of neural progenitor cells. 
Experimental models of brain tumours in the 
developing mouse implicated known brain precursor 
zones as the site of origin of brain tumours induce by 
viral or chemical oncogenesis (Globus and 
Kuhlenbeck, 1944; Copeland and Bigner, 1977; Vick et 
al., 1977; Barnett et al., 1998; Holland et al., 2000; 
Abel et al., 2009). While it is attractive as an extension 
of the cancer stem cell hypothesis to postulate that
gliomas originate from mutations within the neural 
stem cell compartment, the cancer stem cell hypothesis 
does not actually speak to a cell-of-origin. There is 
ample evidence to suggest that cells within the 
progenitor compartment of the brain are more 
susceptible to transformation than committed 
neuroepithelial cells (Holland et al., 2000; Holland, 
2001; Uhrbom et al., 2002). Using a comprehensive 
murine genetic screen in which Rb, p53, and PTEN 
function were abolished, Jacques et al. found that 
gliomas arose only when mutations were directed to the 
neural stem cell compartment and not when these sam 
mutations were present in mature astrocytes (Jacques et 
al., 2010). In this system, the combination of drive  
mutations present was relevant to the identity of the
resulting tumour, specifically in this case, whether 
mutant mice developed gliomas or primitive 
neuroectodermal tumours. However, the possession of 
a non-committed state may not be necessary for a cell 
to undergo gliomagenesis. Non-stem hematologic cells 
have been shown to dedifferentiate and reacquire the 
property of self-renewal as part of the transformation 
process (Krivtsov et al., 2006). Further, the Weiss lab 
has postulated that oligodendrogliomas arise from 
transformation of oligodendrocyte precursor cells 
rather than neural stem cells (Persson et al., 2010). In 
breast cancer and leukemia, founder mutations in 
different cell populations within the mammary tissue or 
hematopoietic cell hierarchy have been found to result 
in the development of divergent breast cancer subtypes 
or different types of leukemia, respectively. Similarly, 
it may be the case that glioma grade and histology are 
dependent not only upon the types of mutations that
occur during transformation but also on the identity of 
the cell in which transformation initially occurs. 
Gliomas and the cancer stem cell 
hypothesis: next steps 
Whether the cancer stem cell hypothesis is relevant to 
glioma biology is finally important because of the 
human cost of our incomplete understanding of these 
diseases. So far, the treatments that we have employed 
for patients with glioblastoma have been relatively 
nonspecific measures to relieve mass effect (i.e. 
surgery) and to cause tumour cell dysfunction or death 
(i.e. radiation and alkylating chemotherapy). They ave 
failed. While biological agents have yet to show benefit 
as therapies for glioblastoma, I suspect that it isonly 
through biology that we are going to make meaningful 
advances in the treatment of this disease. 
Numerous questions remain. For example, what should 
we make of the cellular heterogeneity seen in 
glioblastoma? Even among BTSCs, for example, 
tumours appear to have multiple BTSC populations, 
each possessing different properties in vitro (Beier t 
al., 2007; Chen et al., 2010). Are different cell 
compartments responsible for different aspects of 
tumour behavior? For example, are some cells 
responsible for local growth within or just adjacent to 
the tumour mass, and others responsible for distant 
invasion? What is the import of non-cancerous cells –
such as endothelial cells, microglia, immune cells and 
astrocytes– that are present within the tumour mass? 
Are these cells reactive? Or are they recruited to the 
tumour by glioma cells? How do interactions between 
cancer cells and the surrounding cellular stroma effect 
tumour behavior? 
Second, where is the niche for glioma cells in vivo? Are 
there in fact, as is the case in the bone marrow, multiple 
niches? Are glioma cells within a hypoxic niche 
different from those within a vascular niche? Do they 
both house cancer stem cells? Are the cells residing in 
these divergent niches resistant to cell death because of 
divergent biological properties? Does the niche itslf 
provide additional protections to glioma cells that are 
independent of DNA damage response? 
Third, is the hierarchical relationship among glioma 
cells implied by the cancer stem cell hypothesis 
unidirectional in nature? In other words, can non-stem 
glioma cells give rise to BTSCs? Work from the 
induced pluripotency field has demonstrated that 
minimal genetic changes can initiate whole-genome 
programmatic changes that can reverse fate 
commitment in mature cells (Hanna et al., 2010). Not
inconsequentially, many of the transcription factors that 
have been found to be relevant to induced pluripotency 
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are mutated in cancer, and specifically in glioblastoma. 
In breast cancer cells, epigenetic modifications driven 
by extrinsic signaling cues appear capable of directing 
cells from a non-stem to a stem-like phenotype 
(Chaffer et al., 2011). Could BTSCs and non-stem 
glioma cells be fluid in their relationship? If so, what 
implications would this fluidity have for interventions 
directed against each of these cell compartments? 
Finally, the cancer stem cell hypothesis, if it indee  
explains the biology of gliobastoma beyond the clona  
evolution model, should have deep implications for 
how we care for patients with this disease. Beyond the 
need to develop new therapies to target BTSCs, it is
likely that delineating the biology of these cells will 
allow us to refine the manner in which we deliver 
chemotherapy and radiation. What is the appropriate 
treatment scheme for radiation delivery? Should 
chemotherapy be given as an adjunct or following its 
completion? We are far from fully understanding 
glioblastoma, and as a result, must still work to develop 
the foundation from which to approach its treatment. 
BTSCs and glioma: conclusion 
Whether the cancer stem cell hypothesis is the key to 
understanding the basic biology of glioblastoma or 
simply one of many formulations by which we can 
explain glioma cell evasion of treatment-induced cell
death, it is likely that we have only begun to delin ate 
the manner in which lessons from the stem cell field 
can enhance our understanding of gliomas. 
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